Back to Search Start Over

Genotype and brain pathology phenotype in children with tuberous sclerosis complex.

Authors :
Overwater IE
Swenker R
van der Ende EL
Hanemaayer KB
Hoogeveen-Westerveld M
van Eeghen AM
Lequin MH
van den Ouweland AM
Moll HA
Nellist M
de Wit MY
Source :
European journal of human genetics : EJHG [Eur J Hum Genet] 2016 Dec; Vol. 24 (12), pp. 1688-1695. Date of Electronic Publication: 2016 Jul 13.
Publication Year :
2016

Abstract

Structural brain malformations associated with Tuberous Sclerosis Complex (TSC) are related to the severity of the clinical symptoms and can be visualized by magnetic resonance imaging (MRI). Tuberous Sclerosis Complex is caused by inactivating TSC1 or TSC2 mutations. We investigated associations between TSC brain pathology and different inactivating TSC1 and TSC2 variants, and examined the potential prognostic value of subdivision of TSC2 variants based on their predicted effects on TSC2 expression. We performed genotype-phenotype associations of TSC-related brain pathology on a cohort of 64 children aged 1.4-17.9 years. Brain abnormalities were assessed using MRI. Individuals were grouped into those with an inactivating TSC1 variant and those with an inactivating TSC2 variant. The TSC2 group was subdivided into changes predicted to result in TSC2 protein expression (TSC2p) and changes predicted to prevent expression (TSC2x). The TSC2 group was associated with more and larger tubers, more radial migration lines, and more subependymal nodules than the TSC1 group. Subependymal nodules were also more likely to be calcified. Subdivision of the TSC2 group did not reveal additional, substantial differences, except for a larger number of tubers in the temporal lobe and a larger fraction of cystic tubers in the TSC2x subgroup. The severity of TSC-related brain pathology was related to the presence of an inactivating TSC2 variant. Although larger studies might find specific TSC2 variants that have prognostic value, in our cohort, subdivision of the TSC2 group did not lead to better prediction.<br />Competing Interests: R Swenker reports financial assistance from Novartis. MCY de Wit reports grants from Dutch Epilepsy Foundation, and grants and non-financial support from Novartis outside the submitted work; and the Erasmus MC received honoraria from Novartis for educational lectures presented by the author. The remaining authors declare no conflict of interest.

Details

Language :
English
ISSN :
1476-5438
Volume :
24
Issue :
12
Database :
MEDLINE
Journal :
European journal of human genetics : EJHG
Publication Type :
Academic Journal
Accession number :
27406250
Full Text :
https://doi.org/10.1038/ejhg.2016.85